

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Edoxaban tosylate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Daiichi Sankyo (edoxaban tosylate) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Anticoagulation Europe • Black Health Agency • British Lung Foundation • Equalities National Council • Lifeblood: The Thrombosis Charity • Muslim Council of Britain • Muslim Health Network • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Cardiovascular Society • British Geriatrics Society • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Thoracic Society • Clinical Leaders of Thrombosis (CLOT) • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society of Vascular Nurses • United Kingdom Clinical Pharmacy Association • Vascular Society of Great Britain and Ireland 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Actavis UK (warfarin) • Alliance Pharma (acenocoumarol) • Amdipharm Mercury Pharmaceuticals (phenindione) • Bayer (rivaroxaban) • Boehringer Ingelheim (dabigatran) • Bristol Laboratories (warfarin) • Crescent Pharma (warfarin) • GlaxoSmithKline (fondaparinux) • LEO Pharma (tinzaparin) • Pfizer (dalteparin) • Sandoz (warfarin) • Sanofi (enoxaparin) • Taro Pharmaceuticals UK (warfarin) • Teva (warfarin)

Appendix B

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Bracknell and Ascot CCG • NHS England • NHS Slough CCG • Welsh Government 	<ul style="list-style-type: none"> • Zentiva (warfarin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Antithrombotic Trialists' (ATT) Collaboration • Cochrane Peripheral Vascular Disease Group • Health Research Authority • MRC Clinical Trials Unit • National Institute for Health Research • National Centre for Anticoagulation Training • National Centre for Cardiovascular Preventions and Outcomes • Thrombosis Research Institute • Wellcome Trust <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • BMJ-TAG • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed

any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.